Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.

William J SandbornNervin LawendySilvio DaneseChinyu SuEdward V LoftusAilsa HartIris DotanAdérson O M C DamiãoDonna T JuddXiang GuoIrene ModestoWenjin WangJulian Panés

Published in: Alimentary pharmacology & therapeutics (2021)

Tofacitinib demonstrated consistent safety up to 7.0 years. Data collected up to Month 36 support long-term efficacy beyond the 52-week maintenance study.

Keyphrases

ulcerative colitis
rheumatoid arthritis
randomized controlled trial
machine learning
electronic health record
big data
artificial intelligence
combination therapy
deep learning